MedTrace Logo

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

NCT00203125 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2011-04-12

No results posted yet for this study

Summary

This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo

Conditions

Interventions

DRUG

rasagiline mesylate

0.5 or 1 mg oral, once-daily

OTHER

tyramine

50 mg once daily

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Phyllis Salzman, Ph.D. · Teva Neuroscience, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2003-01-31
Completion
2003-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203125 on ClinicalTrials.gov